Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers.

导出 OA

翻译打印收藏纠错

第一作者： Konstantina,Kontopoulou

第一单位： Department of Microbiology, 'G. Gennimatas' General Hospital, Thessaloniki, Greece.

作者： Konstantina,Kontopoulou ^[1] ; Alexandra,Ainatzoglou ^[2] ; Athina,Ifantidou ^[1] ; Christos T,Nakas ^[3] ; Georgia,Gkounti ^[4] ; Vasilios,Adamopoulos ^[1] ; Nikitas,Papadopoulos ^[1] ; Georgios,Papazisis ^[5]

作者单位： Department of Microbiology, 'G. Gennimatas' General Hospital, Thessaloniki, Greece. ^[1] Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. ^[2] Laboratory of Biometry, University of Thessaly, Phytokou Str.38446, Nea Ionia/Volos, Magnesia, Greece.;University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. ^[3] Department of Cardiology, 'G. Gennimatas' General Hospital, Thessaloniki, Greece. ^[4] Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.;Clinical Trials Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. ^[5]

关键词 Greece Pfizer-BioNTech BNT162b2 mRNA SARS-CoV-2 healthcare workers immunogenicity vaccine